Glycogen synthase kinase 3: a drug target for CNS therapies
- 22 April 2004
- journal article
- review article
- Published by Wiley in Journal of Neurochemistry
- Vol. 89 (6), 1313-1317
- https://doi.org/10.1111/j.1471-4159.2004.02422.x
Abstract
Glycogen synthase kinase3 (GSK3) is emerging as a prominent drug target in the CNS. The most exciting of the possibilities of GSK3 lies within the treatment of Alzheimer's disease (AD) where abnormal increases in GSK3 levels and activity have been associated with neuronal death, paired helical filament tau formation and neurite retraction as well as a decline in cognitive performance. Abnormal activity of GSK3 is also implicated in stroke. Lithium, a widely used drug for affective disorders, inhibits GSK3 at therapeutically relevant concentrations. Thus while the rationale remains testable, pharmaceutical companies are investing in finding a selective inhibitor of GSK3. In the present review, we summarize the properties of GSK3, and discuss the potential for such a therapy in AD, and other CNS disorders.Keywords
This publication has 48 references indexed in Scilit:
- PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutationsThe EMBO Journal, 2004
- Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418Journal of Biological Chemistry, 2003
- Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammationMedicinal Research Reviews, 2002
- The GSK3β signaling cascade and neurodegenerative diseaseCurrent Opinion in Neurobiology, 2002
- Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from deathJournal of Neurochemistry, 2001
- Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic MiceJournal of Biological Chemistry, 2000
- Sequential phosphorylation of Tau by glycogen synthase kinase‐3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer‐specific epitope of antibody AT100 and requires a paired‐helical‐filament‐like conformationEuropean Journal of Biochemistry, 1998
- Phosphorylation of the cAMP Response Element Binding Protein CREB by cAMP-Dependent Protein Kinase A and Glycogen Synthase Kinase-3 Alters DNA-Binding Affinity, Conformation, and Increases Net ChargeBiochemistry, 1998
- Glycogen synthase kinase 3β is identical to tau protein kinase I generating several epitopes of paired helical filamentsFEBS Letters, 1993
- Alzheimer's disease: a cell biological perspectiveScience, 1992